Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …

The calcineurin‐inhibitor tacrolimus (Tac) provides an acceptable balance between
prevention of allograft rejection and drug‐related adverse effects, making it the standard of …

Tacrolimus was discovered in 1984 and entered clinical use shortly thereafter, contributing
to successful solid organ transplantation across the globe. In this review, we cover …

Demand-side policies to encourage the use of generic medicines are important to increase
their use. A plethora of different demand-side policies has already been initiated by …

Objective To compare the clinical efficacy and bioequivalence of generic
immunosuppressive drugs in patients with solid organ transplants. Design Systematic …

Objective To test the current US Food and Drug Administration (FDA) bioequivalence
standard in a comparison of generic and brand‐name drug pharmacokinetic (PK) …

Tacrolimus is the cornerstone of immunosuppressive therapy after kidney transplantation
(KT), but its use is complicated by a narrow therapeutic index and high inter-and intra-patient …